
Opinion|Videos|August 30, 2024
Challenges in Risk Assessment and Biomarkers in Treatment Recommendations
The panelists examine the challenges and limitations they've faced when using the Gleason score for risk assessment in prostate cancer patients, while also highlighting how biomarker testing has informed and guided their treatment strategies.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- What are some challenges or limitations you have encountered when using the Gleason score when assessing risk in your prostate cancer patients?
- In your clinical experience, have biomarkers guided your treatment recommendations? If so which one(s)?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
3
FDA approves first-line Zenflow system for the treatment of BPH
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5























